Biocon Biologics Limited, a global biosimilars company and a subsidiary of Biocon Ltd., has joined hands with the National Cancer Society of Malaysia (NCSM) to launch a new Patient Assistance Program (PAP). This initiative aims to improve access to affordable, high-quality cancer treatments for underserved patients in Malaysia.
Through this partnership, Biocon Biologics will supply biosimilar medicines from its oncology portfolio, including Trastuzumab, Pegfilgrastim, and Bevacizumab, to support cancer treatment in the country. The program will be managed by NCSM, which will oversee patient enrollment and the distribution of medicines as part of its broader healthcare services.
The initiative will begin with the distribution of bTrastuzumab to breast cancer patients who are currently facing treatment delays due to budget limitations.
The Memorandum of Understanding (MoU) was officially signed during the National Cancer Congress Malaysia 2025, underscoring both organizations’ commitment to advancing patient-centric healthcare and strengthening cancer care infrastructure in Malaysia.
Biocon Biologics brings its global expertise in biosimilars to the partnership, while NCSM contributes its extensive experience in community outreach and patient support. Together, they aim to reduce the treatment burden for patients and make life-saving therapies more accessible.
This program builds on Biocon Biologics’ earlier success in Malaysia, where it provided insulin therapy and support to over 345,000 diabetes patients. The company is now extending its focus to oncology, using strategic collaborations to expand its impact on public health.
